Healthgen Biotech
its OsrHSA injection (奥福民®) became the world's first NMPA-approved rHSA therapeutic injection in July 2025 — also the first globally-approved rice-derived recombinant protein drug — backed by a multicentre, randomised, double-blind,…
- Country
- China
- Ticker
- SSE:688765
World's first NMPA-approved rHSA injection; first globally-approved rice-derived recombinant protein drug
cn
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant human serum albumin (rHSA) | specialty-fine-chem | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.